Supplementary Data — Peginterferon Lambda for COVID-19: real-time meta analysis of 5 studies

@CovidAnalysis, November 2025, Version 8V8
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ILIAD Cohort A Feld (DB RCT) 0% 1.00 [0.07-15.3] hosp. 1/30 1/30 Improvement, RR [CI] Treatment Control ILIAD Cohort A Feld (DB RCT) 75% 0.25 [0.03-2.11] ER visit 1/30 4/30 ILIAD Cohort A Feld (DB RCT) 66% 0.34 [0.09-0.91] viral+ 6/30 11/30 COVID-Lambda Jagannat.. (SB RCT) 0% 1.00 [0.15-6.87] hosp. 2/60 2/60 COVID-Lambda Jagannat.. (SB RCT) -6% 1.06 [0.72-1.56] no recov. 60 (n) 60 (n) COVID-Lambda Jagannat.. (SB RCT) -14% 1.14 [0.14-9.17] viral load 60 (n) 60 (n) TOGETHER Reis (DB RCT) 27% 0.73 [0.21-2.58] death 4/931 6/1,018 TOGETHER Reis (DB RCT) 61% 0.39 [0.05-1.95] death 1/931 4/1,018 TOGETHER Reis (DB RCT) 42% 0.58 [0.34-0.96] hosp. 21/931 40/1,018 TOGETHER Reis (DB RCT) 51% 0.49 [0.30-0.76] hosp./ER 25/931 57/1,018 Kim (SB RCT) -200% 3.00 [0.14-63.2] ICU 1/7 0/7 Kim (SB RCT) -25% 1.25 [0.57-2.73] hosp. time 7 (n) 7 (n) Kim (SB RCT) 12% 0.88 [0.31-2.44] viral+ 3/6 4/7 Kim (SB RCT) -67% 1.67 [0.63-4.42] viral+ 5/7 3/7 ILIAD Cohort B Kandel (DB RCT) -32% 1.32 [0.60-2.86] 7-point status 48 (n) 46 (n) Peginterferon lambda COVID-19 outcomes c19early.org November 2025 Favors peg.. lambda Favors control
Fig. S1. All outcomes.